Progression of cardiac hypertrophy during long term calcium antagonist treatment with tiapamil.
Hypertension complicated by left ventricular hypertrophy is associated with increased morbidity as it leads to left ventricular systolic and diastolic dysfunction. Thus, in the treatment of hypertension, a desirable goal is the regression of left ventricular hypertrophy. Tiapamil, a new calcium antagonist, was evaluated in a 58 week open study to determine its effect on left ventricular mass in relation to its ability to lower blood pressure. Twenty adult patients with mild to moderate hypertension were entered into the study. Blood pressure was significantly reduced from 166 +/- 16/105 +/- 7 mmHg before treatment to 142 +/- 9/88 +/- 4 mmHg after 58 weeks. The posterior and interventricular septal wall thickness and left ventricular systolic dimension did not show any significant change by the end of the trial. On the other hand, left ventricular diastolic dimension, ejection fraction, and left ventricular mass increased significantly (P less than 0.05). Other laboratory parameters were not affected during treatment with the exception of a moderate decrease in the blood glucose. Side effects were mild and self-limiting, and no patients were withdrawn from the study. Although tiapamil appears to be an effective and well-tolerated drug in mild to moderate hypertension, it failed to reduce left ventricular mass.